News

FDA Approves MyChoice CDx to Expand Access to Niraparib in Ovarian Cancer

News, Precision Medicine /

The U.S. Food and Drug Administration has approved MyChoice® CDx as the first companion diagnostic test to identify patients with HRD-positive advanced ovarian cancer who can benefit from the PARP inhibitor niraparib. MyChoice CDx uses advanced genetic sequencing to analyze BRCA1/2 genes and signs of genomic instability, helping find about 34% more eligible patients compared […]

FDA Approves MyChoice CDx to Expand Access to Niraparib in Ovarian Cancer Read More »

New Hydrogel Model Mimics Tumor Stiffening in Pancreatic Ductal Adenocarcinoma to Improve Cancer Research

Research Advances /

Scientists have created a new hydrogel model that mimics how pancreatic tumors become stiffer over time, offering a more realistic way to study Pancreatic Ductal Adenocarcinoma (PDAC). The advance could help researchers better understand why this aggressive cancer resists treatment and spreads so easily. PDAC tumors are surrounded by a dense, stiff environment caused by

New Hydrogel Model Mimics Tumor Stiffening in Pancreatic Ductal Adenocarcinoma to Improve Cancer Research Read More »

Mayo Clinic Develops Milk-Based Nanoparticle Gene Therapy for Targeted Treatment of Cholangiocarcinoma

Targeted Therapy /

Researchers at Mayo Clinic have developed a new targeted gene therapy approach for cholangiocarcinoma, a rare and aggressive bile duct cancer. The study, published in JHEP Reports, introduces a precision method that delivers treatment directly to cancer cells while limiting damage to healthy tissue. The system uses small interfering RNA (siRNA) to switch off genes

Mayo Clinic Develops Milk-Based Nanoparticle Gene Therapy for Targeted Treatment of Cholangiocarcinoma Read More »

Scientists Identify MAP4K2 as Key Switch to Boost Cancer Immunity or Control Autoimmunity

Research Advances /

New research has identified MAP4K2 as a key regulator of regulatory T cells (Tregs), offering a new way to control the immune system in both cancer and autoimmune diseases. The study shows that MAP4K2 controls the production of FOXP3, a protein essential for turning regular T cells into suppressive Tregs. It does this by interacting

Scientists Identify MAP4K2 as Key Switch to Boost Cancer Immunity or Control Autoimmunity Read More »

Genomic Test Helps Melanoma Patients Safely Avoid Lymph Node Surgery

Precision Medicine /

New data shows that the i31-SLNB genomic test can help identify melanoma patients who may safely skip sentinel lymph node biopsy. The test is part of the DecisionDx-Melanoma and combines a 31-gene profile with clinical factors such as age and tumor thickness to predict whether cancer has spread to lymph nodes. In a study of

Genomic Test Helps Melanoma Patients Safely Avoid Lymph Node Surgery Read More »

New Optune Pax Device Improves Survival in Pancreatic Cancer

Technology Innovation /

The PANOVA-3 study led to the February 2026 FDA approval of Optune Pax, a new noninvasive device for patients with locally advanced pancreatic cancer. It is used together with standard chemotherapy, including gemcitabine and nab-paclitaxel. The device works by using tumor-treating fields to disrupt cancer cell division. The study showed clear benefits. Median overall survival

New Optune Pax Device Improves Survival in Pancreatic Cancer Read More »

Belzutifan Plus Keytruda Cuts Recurrence Risk in High-Risk Kidney Cancer

Treatment /

The phase 3 LITESPARK-022 trial shows that combining Belzutifan (Welireg) with Pembrolizumab (Keytruda) after surgery significantly lowers the risk of recurrence in patients with high-risk clear cell renal cell carcinoma. The study found a 28% reduction in the risk of recurrence or death compared to Pembrolizumab alone. Overall survival data are still immature, though early

Belzutifan Plus Keytruda Cuts Recurrence Risk in High-Risk Kidney Cancer Read More »

New Study Targets DDX5 to Kill Drug-Resistant Cells in Myeloproliferative Neoplasms

Research Advances /

A new study has identified the RNA helicase DDX5 as an important driver of myeloproliferative neoplasms (MPNs), blood cancers often caused by the JAK2V617F mutation. The research suggests that targeting DDX5 with the small-molecule drug FL118 could help eliminate cancer cells that current treatments fail to destroy. MPNs such as polycythemia vera and myelofibrosis are

New Study Targets DDX5 to Kill Drug-Resistant Cells in Myeloproliferative Neoplasms Read More »

Study Identifies P3H1 Protein as a New Target in Pancreatic Cancer Treatment

Research Advances /

A new study has identified Prolyl 3-hydroxylase 1 (P3H1) as an important driver of pancreatic ductal adenocarcinoma (PDAC) and a potential new treatment target. Researchers found that P3H1 is highly expressed in both human and mouse pancreatic tumors. Patients with higher P3H1 levels tended to have more advanced disease and shorter disease-free survival. In mouse

Study Identifies P3H1 Protein as a New Target in Pancreatic Cancer Treatment Read More »

Ketogenic Diet Shows Potential to Improve Survival in Metastatic Pancreatic Cancer Trial

Clinical Trails /

A Phase II clinical trial suggests that a medically supervised ketogenic diet (MSKD) may help improve outcomes for patients with metastatic pancreatic ductal adenocarcinoma receiving combination chemotherapy with gemcitabine, nab-paclitaxel, and cisplatin. The study included 32 evaluable patients and compared chemotherapy plus the ketogenic diet with chemotherapy plus a usual diet. Results showed encouraging trends

Ketogenic Diet Shows Potential to Improve Survival in Metastatic Pancreatic Cancer Trial Read More »